Effective Evaluation Of Using PIDOTIMOD In Treatment Of Refractory Allergic Rhinitis

Objective:To observe the application effect of Pidotimod in the treatment of refractory Allergic rhinitis.Methods:A total of 68 patients with refractory Allergic rhinitis who were admitted in The First Affiliated Hospital of Dalian Medical University from August 2019 to August 2020 were included in the study.The patients were divided to two groups,the test group and the control group.For the control group,patients were given oral Histamine and Budesonide nasal spray.The test group was given Pidotimod on the basis of the control group.The Nasal symptom score and the Intranasal finding score were used to evaluate the clinical efficacy of general symptoms and nasal symptoms before treatment,two weeks after treatment and four weeks after treatment.Results:Before the test,the Nasal symptom score in the control group were 3.31±0.693,3.25±0.672,3.44±0.716,and 3.19±0.535 in Nasal obstruction,Nasal discharge,Nasal itching and Sneezing respectively.In the test group,the Nasal symptom score were 3.22±0.659,2.75±0.672,3.16±0.723,and 2.94±0.669 respectively.There was no statistical significance between the two groups with P>0.05.The Intranasal finding score in the control group were 1.81±0.397,and 2.69±0.471 in Congestion of inferior turbinate and Amount of discharge respectively.In the test group,the Intranasal finding score were 1.84±0.369 and 2.47±0.621 respectively.There was no statistical significance between the two groups with P>0.05.The paired T test and the Winconxon sign rank test were used for the comparison between the two groups.After two-weeks treatment,the Nasal symptom score in the control group were 2.94±0.669,2.81±0.644,2.75±0.762,and 2.44±0.504 in Nasal obstruction,Nasal discharge,Nasal itching and Sneezing respectively.In the test group,the Nasal symptom score were 1.13±0.751,1.19±0.965,1.03±0.822,and 1.03±0.782 respectively.There was a decrease in symptoms after two-weeks treatment between the control group and the test group with corresponding reductions of 1.81±0.082(61.56%),1.62±0.321(57.65%),1.72±0.06(62.54%),and 1.41±0.278(57.78%)in Nasal obstruction,Nasal discharge,Nasal itching and Sneezing respectively with P<0.05.The Intranasal finding score in the control group were 1.44±0.504 and 2.13±0.609 in Congestion of inferior turbinate and Amount of discharge respectively.In the test group,the Intranasal finding score were 0.53±0.507 and 0.91±0.777 respectively.After four-weeks treatment,the Nasal symptom score in the control group were 2.31±0.693,1.94±0.669,2.13±0.707,and 1.75±0.672 in Nasal obstruction,Nasal discharge,Nasal itching and Sneezing respectively.In the test group,the Nasal symptom score were 0.47±0.507,0.50±0.508,0.44±0.564,and 0.34±0.483 respectively.There was a decrease in symptoms after four-weeks treatment between the test group and the control group with corresponding reductions of 1.84±0.186(79.65%),1.44±0.161(74.22%),1.69±0.143(79.34%),and 1.41±0.189(80.57%)in Nasal obstruction,Nasal discharge,Nasal itching and Sneezing respectively with P<0.05.The Intranasal finding score in the control group were 1.19±644 and 2.00±0.508 in Congestion of inferior turbinate and Amount of discharge respectively.In the test group,the Intranasal finding score were 0.06±0.246 and 0.19±0.397 respectively.Conclusions:Pidotimod demonstrated clinical improvement in Allergic rhinitis treatment.When given with Antihistamine and nasal spray Corticoid,it will help to improve symptoms and physical signs quickly.